Besifloxacin HCl | CAS#405165-61-9 | 141388-76-3

MedKoo Cat#: 300142 | Name: Besifloxacin HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Besifloxacin is a fourth-generation fluoroquinolone antibiotic. The marketed compound is besifloxacin hydrochloride. It was developed by SSP Co. Ltd., Japan, and designated SS734. SSP licensed U.S. and European rights to SS734 for ophthalmic use to InSite Vision Incorporated (OTCBB: INSV) in 2000. InSite Vision developed an eye drop formulation (ISV-403) and conducted preliminary clinical trials before selling the product and all rights to Bausch & Lomb in 2003.

Chemical Structure

Besifloxacin HCl

CAS#405165-61-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 300142

Name: Besifloxacin HCl

CAS#: 405165-61-9 (HCl)

Chemical Formula: C19H22Cl2FN3O3

Exact Mass: 0.0000

Molecular Weight: 430.30

Elemental Analysis: C, 53.03; H, 5.15; Cl, 16.48; F, 4.42; N, 9.77; O, 11.15

Price and Availability

Size	Price	Availability
10mg	USD 250.00	2 Weeks
100mg	USD 550.00	2 Weeks
250mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

BOL 303224a; BOL-303224a; BOL303224a; BOL-303224-A; SS734; SS-734; SS 734; Besifloxacin HCl; Besivance.

IUPAC/Chemical Name

(+)-7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1- cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride.

InChi Key

PMQBICKXAAKXAY-HNCPQSOCSA-N

InChi Code

InChI=1S/C19H21ClFN3O3.ClH/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23;/h7,9-11H,1-6,8,22H2,(H,26,27);1H/t10-;/m1./s1

SMILES Code

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@H](N)CCCC4)=C3Cl)C1=O)O.[H]Cl

Appearance

solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO.

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related: 405165-61-9 (Besifloxacin HCl) 141388-76-3 (Besifloxacin free).

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 430.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Besifloxacin. 2018 Dec 3. PMID: 29999822. 2: Mah FS, Sanfilippo CM. Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections. Ophthalmol Ther. 2016 Jun;5(1):1-20. doi: 10.1007/s40123-016-0046-6. Epub 2016 Mar 24. PMID: 27010720; PMCID: PMC4909673. 3: Chang MH, Fung HB. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. Clin Ther. 2010 Mar;32(3):454-71. doi: 10.1016/j.clinthera.2010.03.013. PMID: 20399984. 4: O'Brien TP. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012 Jun;29(6):473-90. doi: 10.1007/s12325-012-0027-7. Epub 2012 Jun 20. PMID: 22729919. 5: Mahvan TD, Hornecker JR, Buckley WA, Clark S. The role of besifloxacin in the treatment of bacterial conjunctivitis. Ann Pharmacother. 2014 May;48(5):616-25. doi: 10.1177/1060028014524175. Epub 2014 Feb 24. PMID: 24566460. 6: Kassaee SN, Mahboobian MM. Besifloxacin-loaded ocular nanoemulsions: design, formulation and efficacy evaluation. Drug Deliv Transl Res. 2022 Jan;12(1):229-239. doi: 10.1007/s13346-021-00902-z. Epub 2021 Feb 11. PMID: 33575973. 7: Bertino JS, Zhang JZ. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. Expert Opin Pharmacother. 2009 Oct;10(15):2545-54. doi: 10.1517/14656560903213413. PMID: 19743941. 8: Deschênes J, Blondeau J. Besifloxacin in the management of bacterial infections of the ocular surface. Can J Ophthalmol. 2015 Jun;50(3):184-91. doi: 10.1016/j.jcjo.2014.12.013. PMID: 26040217. 9: Nafziger AN, Bertino JS Jr. Besifloxacin ophthalmic suspension for bacterial conjunctivitis. Drugs Today (Barc). 2009 Aug;45(8):577-88. PMID: 19927224. 10: Jesus JISDS, Lourenço FR, Ishida K, Barreto TL, Avino VC, Neto EDS, Bou- Chacra NA. Besifloxacin Nanocrystal: Towards an Innovative Ophthalmic Preparation. Pharmaceutics. 2022 Oct 18;14(10):2221. doi: 10.3390/pharmaceutics14102221. PMID: 36297656; PMCID: PMC9609799. 11: Tótoli EG, Salgado HRN. Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods. Crit Rev Anal Chem. 2018 Mar 4;48(2):132-142. doi: 10.1080/10408347.2018.1429885. Epub 2018 Feb 2. PMID: 29345957. 12: Wang JJ, Gao XY, Li HZ, Du SS. Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis. Int J Ophthalmol. 2019 Dec 18;12(12):1898-1907. doi: 10.18240/ijo.2019.12.13. PMID: 31850176; PMCID: PMC6901884. 13: Carter NJ, Scott LJ. Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70(1):83-97. doi: 10.2165/11203820-000000000-00000. PMID: 20030427. 14: Bhatnagar S, Saju A, Cheerla KD, Gade SK, Garg P, Venuganti VVK. Corneal delivery of besifloxacin using rapidly dissolving polymeric microneedles. Drug Deliv Transl Res. 2018 Jun;8(3):473-483. doi: 10.1007/s13346-017-0470-8. PMID: 29288357. 15: Wang JJ, Gao XY, Li HZ, Du SS. The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis. Int J Ophthalmol. 2019 Jun 18;12(6):1027-1036. doi: 10.18240/ijo.2019.06.24. Retraction in: Int J Ophthalmol. 2019 Sep 18;12(9):1401. PMID: 31236364; PMCID: PMC6580202. 16: Khimdas S, Visscher KL, Hutnik CM. Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis. Ophthalmol Eye Dis. 2011 Mar 20;3:7-12. doi: 10.4137/OED.S4102. PMID: 23861618; PMCID: PMC3661456. 17: Majmudar PA, Clinch TE. Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients. Cornea. 2014 May;33(5):457-62. doi: 10.1097/ICO.0000000000000098. PMID: 24637269; PMCID: PMC4195578. 18: Comstock TL, Karpecki PM, Morris TW, Zhang JZ. Besifloxacin: a novel anti- infective for the treatment of bacterial conjunctivitis. Clin Ophthalmol. 2010 Apr 26;4:215-25. doi: 10.2147/opth.s9604. PMID: 20463787; PMCID: PMC2861926. 19: Karpecki P, Depaolis M, Hunter JA, White EM, Rigel L, Brunner LS, Usner DW, Paterno MR, Comstock TL. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double- masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009 Mar;31(3):514-26. doi: 10.1016/j.clinthera.2009.03.010. PMID: 19393842. 20: Schechter BA, Parekh JG, Trattler W. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study. J Ocul Pharmacol Ther. 2015 Mar;31(2):114-21. doi: 10.1089/jop.2014.0039. Epub 2014 Nov 19. PMID: 25409447.